Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands to better understand their contribution to cancer immunosurveillance and their therapeutic applicability.
A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes weresensitized against 170 selected nonC-TL to isolate antigen-specific T-cell receptors and evaluate their therapeutic potential.
Source: Healthcare Press (healthcarepress.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance - Molecular CancerBackground Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. Main body Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility. Conclusions A deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.
Source: BioMedCentral - 🏆 22. / 71 Read more »
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance - Molecular CancerBackground Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. Main body Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility. Conclusions A deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.
Source: BioMedCentral - 🏆 22. / 71 Read more »
Attacker who punched man in the face still not identified after six monthsThe 'unprovoked attack' happened on King Street in Whalley in September 2022 and police are renewing a CCTV appeal
Source: LiveLancs - 🏆 10. / 87 Read more »
BugBitten A tsetse fly aphrodisiac is identified
Source: BioMedCentral - 🏆 22. / 71 Read more »
Sainz: Ferrari has set development path amid F1 race pace weakness🗣️'We know where to develop the car, we just need time.' Carlos Sainz says his Ferrari F1 team had already identified its 2023 development path in Bahrain, with its tyre management struggles confirmed last weekend in Jeddah ⬇️ Same old story from Ferrari. “We are getting there, just a little longer “ 😂 Two down - 21 more to go! ForzaSF 🇮🇹 What time is there without testing and with a budget cap?
Source: autosport - 🏆 90. / 53 Read more »
Researchers identify the origin of subset of autoantibodies that worsen lupusIn an effort to understand the origin of systemic lupus erythematosus and why some patients present with more severe disease than others, Johns Hopkins Medicine researchers say they have identified a type of autoantibody that may worsen the condition and have also found how these autoantibodies originate. They say their findings have implications for biomarker testing in lupus and may help identify patients that need early and aggressive treatment.
Source: medical_xpress - 🏆 101. / 51 Read more »